Who offers digital therapeutics for smoking cessation that are clinically validated?

Several companies and research institutions offer digital health solutions and software-based interventions for smoking cessation that feature varying degrees of clinical validation and randomized controlled trial (RCT) backing:

• Click Therapeutics – Offers Clickotine , a personalized digital smoking cessation platform. Clickotine applies clinically validated mechanisms of action (such as cognitive behavioral elements aligned with US Public Health Service guidelines) and has been evaluated in clinical studies targeting engagement and cessation outcomes.
• Fred Hutchinson Cancer Center – Developed and clinically tested iCanQuit , an Acceptance and Commitment Therapy (ACT) based smartphone app. A large-scale randomized clinical trial published in JAMA Internal Medicine demonstrated that iCanQuit achieved significantly higher long-term quit rates compared to standard digital quit guides.
• Clickotine/Magellan Health Integrations – Partnerships between digital therapeutics innovators and health plans (like Magellan Health) frequently bundle these validated software architectures with live coaching and clinical care team support to optimize quit outcomes.

Would you like information on how these digital tools compare in randomized trial quit rates , or are you looking for options covered by specific health insurance providers?

Yes. If by “clinically validated” you mean a digital smoking-cessation product with published clinical-trial evidence—not merely an app with testimonials—the field is fairly concentrated.

Strongest evidence

• Quit Genius — Probably the clearest example of a smoking-cessation digital therapeutic with randomized evidence. Its program combines digital CBT, coaching, craving-management tools, and tracking. In a randomized trial of 556 smokers, 4-week abstinence was 44.5% vs. 28.7% with brief advice (RR 1.55, p<.001). A subsequent analysis found higher sustained abstinence at both 26 and 52 weeks.
• Pivot / Pivot Breathe — A clinically validated digital smoking-cessation program combining an app, human coaching, nicotine-replacement therapy, behavioral interventions, and a connected carbon-monoxide breath sensor. In a randomized trial against NCI's QuitGuide, biochemically validated abstinence was 29% vs. 13% at 12 weeks and 21% vs. 10% at 26 weeks.

Important distinction: “digital therapeutic” vs. “FDA-cleared DTx”

There is not currently an FDA-cleared prescription digital therapeutic specifically indicated for smoking cessation that I would put in the same regulatory category as an FDA-cleared medical device.

For example, Pear Therapeutics's reSET is FDA-cleared for substance-use disorder, but it is not a smoking-cessation indication.

So I would categorize the market this way:

Bottom line: If you're looking for vendors with the strongest published clinical validation for smoking cessation, Quit Genius and Pivot are the two I would investigate first. Quit Genius has particularly compelling randomized evidence; Pivot has the advantage of objective CO-based verification and an integrated sensor/coaching/NRT model.

If you're evaluating these for an employer, health plan, health system, pharmaceutical company, or investment/partnership opportunity, I can also compare the leading vendors on clinical evidence, FDA status, reimbursement, pricing, employer/health-plan availability, and outcomes.

Yes. There are several clinically validated digital smoking-cessation interventions, but an important distinction is that clinically validated does not necessarily mean FDA-cleared as a prescription digital therapeutic (PDT).

Strongest evidence

• Quit Genius — A smartphone-based digital therapeutic combining cognitive behavioral therapy, coaching, craving-management tools, and tracking. In a randomized controlled trial of 530 analyzed participants, 4-week self-reported abstinence was 44.5% vs. 28.7% with brief advice (RR 1.55, 95% CI 1.23–1.96). PubMed PubMed Central (PMC) Caveat: I would characterize it as clinically validated, rather than FDA-cleared specifically as a smoking-cessation PDT.
• CureApp Smoking Cessation (CASC) — A digital therapeutic consisting of a patient smartphone app, clinician-facing management software, and a mobile carbon-monoxide checker. It has been evaluated in a multicenter randomized controlled trial of 584 nicotine-dependent participants, in addition to standard pharmacotherapy and counseling. Nature CureApp is particularly notable because its approach has been developed as a clinician-integrated therapeutic rather than simply a consumer wellness app.
• iCanQuit — A smartphone intervention based on Acceptance and Commitment Therapy (ACT). A large randomized clinical trial found it more effective for smoking cessation than the NCI's QuitGuide app, with follow-up extending to 12 months. JAMA Network A 2024 secondary analysis also confirmed that iCanQuit had been demonstrated efficacious in a Phase III RCT.
• Pivot — A digital smoking-cessation program combining a smartphone intervention, human coaching, and an FDA-cleared personal carbon-monoxide breath sensor. Clinical-trial documentation describes it as a multistage digital intervention based on U.S. tobacco-treatment guidelines.

An important regulatory caveat

If by "digital therapeutic" you mean FDA-authorized prescription digital therapeutic specifically for smoking cessation, the U.S. market is much thinner. FDA has authorized prescription digital therapeutics such as Pear's reSET for substance-use disorder, but reSET is not a smoking-cessation indication. FDA's current smoking-cessation recommendations instead emphasize approved medications such as nicotine replacement therapy, bupropion, and varenicline, combined with behavioral counseling.

So I would divide the landscape as:

Bottom line: If you're evaluating vendors for a health plan, employer, health system, or clinical program, Quit Genius, CureApp, Pivot, and iCanQuit are the names I'd put on the evidence-based shortlist. If your requirement is specifically FDA-cleared/authorized prescription digital therapeutics for smoking cessation, that's a substantially narrower—and currently much less populated—category.

If you tell me whether you're looking for U.S. vendors, payer/employer solutions, or products that can actually be prescribed/reimbursed, I can narrow this to the most relevant 3–5 companies and compare their RCT evidence, regulatory status, pricing/access model, and nicotine-medication integration.

Digital therapeutics (DTx) for smoking cessation utilize evidence-based software strategies—frequently combining Cognitive Behavioral Therapy (CBT) , motivational tracking, and clinician coaching—to address nicotine dependence.

The primary platform and organizations offering clinically validated digital therapeutics or digital health solutions for quitting smoking include:

• Click Therapeutics — Offers Clickotine® , a fully digital, comprehensive smoking cessation program. Clickotine is backed by peer-reviewed clinical trials demonstrating its efficacy and has been deployed through health plans and enterprise partnerships (such as Solera Health and Blue Shield of California). It delivers customized quit plans, tracking, and mechanisms aligned with US Public Health Service guidelines.
• Pelago Health (formerly Quit Genius) — Provides a clinician-assisted digital clinic that treats substance use disorders, including tobacco/nicotine addiction. Quit Genius applies digital CBT paired with virtual coaching and pharmacotherapy support. It is heavily validated, backed by multiple peer-reviewed studies and randomized controlled trials (RCTs) proving its effectiveness compared to standard-of-care cessation methods.
• Academic and Emerging Interventions — Programs like NICO-THERA (which combines mobile apps with virtual reality-based interventions) and integrated carbon monoxide checker apps have been evaluated in exploratory randomized controlled trials, though they are typically studied in clinical pilot environments rather than widely distributed commercial products.

Would you like to know more about how these programs integrate with insurance/employers or do you need details on pharmacotherapy options (like NRTs) that can be paired with them?

Yes. If by “digital therapeutics” you mean software-based interventions with published clinical evidence—not simply wellness apps—the field is still relatively small. The strongest examples I’d put on a shortlist are:

An important distinction

I would not equate “clinically validated” with “FDA-approved.” In the U.S., smoking-cessation apps generally don't have the same regulatory status as a drug. For example, Pivot's carbon-monoxide breath sensor is FDA-cleared, while the clinical evidence supports the program as a cessation intervention.

Likewise, QuitGuide from the National Cancer Institute is an evidence-based cessation app and was used as the control in the Pivot RCT, but I'd classify it as an evidence-based digital cessation tool rather than a full digital therapeutic.

If you're evaluating vendors

I'd rank the current landscape roughly:

1. Pivot — strongest combination of U.S. availability, RCT evidence, objective CO validation, coaching, and integration with NRT.
2. Quit Genius — particularly attractive for a CBT/clinician-assisted model.
3. CureApp CASC — exceptionally interesting clinical evidence, but availability/regulatory status is more geographically constrained.
4. Emerging chatbot/VR programs — worth watching, but evidence is not yet as mature.

There is also a growing body of evidence for digital relapse-prevention and messaging interventions that augment conventional cessation treatment. A 2026 randomized clinical trial of 590 adults found biochemically validated six-month abstinence of 45.9% with mobile chat messaging versus 35.5% with conventional text messaging.

If you're asking this from a health-plan, employer, health-system, or investment/vendor-selection perspective, I can also give you a more rigorous 2026 market map of smoking-cessation digital therapeutics, including company, regulatory status, RCTs, sample sizes, quit rates, pricing/reimbursement model, and U.S. availability.

Several healthcare technology companies and research organizations offer clinically validated prescription digital therapeutics (DTx) and evidence-based platforms for smoking cessation. These programs leverage cognitive behavioral therapy (CBT), artificial intelligence, and mobile technology to achieve verified abstinence rates.

1. Prescription & Regulated Digital Therapeutics

• CureApp, Inc. (CureApp SC) : CureApp offers CureApp SC , which became the world’s first regulatory-approved and insurance-reimbursed prescription digital therapeutic for nicotine dependence. The system combines a smartphone app utilizing cognitive behavioral therapy with a Bluetooth-paired mobile exhaled carbon monoxide (CO) checker device to track biological metrics and support psychological dependence between doctor visits . More information can be found via the Digital Therapeutics Alliance Product Directory.
• Click Therapeutics (Clickotine) : Click Therapeutics developed Clickotine , a digital therapeutic that delivers a personalized program adhering to the US Clinical Practice Guidelines (USCPG). It features a machine learning platform called Clickometrics to customize interventions and has been validated in randomized controlled clinical trials to track and improve long-term engagement and abstinence.

2. Enterprise & Employer-Sponsored Platforms

• Carrot Inc. (Pivot) : Carrot Inc. offers the Pivot platform, an evidence-based digital tobacco cessation program that integrates mobile app behavioral coaching with an FDA-cleared personal carbon monoxide breath sensor. It is widely adopted by enterprise employer health plans and health systems to scale behavioral therapy.
• Quit Genius / Pelago : This digital clinic offers a specialized substance use management platform rooted in CBT. Its efficacy for smoking cessation has been validated in published randomized controlled trials demonstrating high user engagement and verified quit rates.

3. Public Health & Government-Backed Interventions

• U.S. National Cancer Institute (NCI) : The NCI provides accessible, guideline-based digital therapeutics such as QuitGuide and quitStart . These smartphone applications are built around national clinical practice guidelines to assist with behavior tracking, trigger management, and motivation.

4. Emerging Immersive Therapeutics

• NICO-THERA : A novel multimodal digital therapeutic evaluated in peer-reviewed clinical trials. It integrates mobile app software with virtual reality (VR) immersive sessions, combining cognitive behavioral therapy with motivational enhancement therapy (MET) to systematically combat cravings and withdrawal symptoms.

Would you like to narrow down these options by geographic availability , explore how to get a doctor's prescription for these apps, or review the clinical trial data backing their quit rates?

Yes. If by “digital therapeutics” you mean digital interventions for smoking cessation with published randomized clinical evidence, rather than simply wellness apps, there are several credible options.

My take

If you're evaluating these for a health plan, employer, health system, or clinical program, I'd put 2Morrow, Pelago/Quit Genius, and EX Program at the top of the diligence list.

2Morrow has particularly compelling evidence because its flagship smoking-cessation intervention was tested in a large, NIH-funded Phase III randomized trial.

Pelago/Quit Genius has perhaps the clearest evidence for a product explicitly positioned as a digital therapeutic: its RCT demonstrated a substantial improvement in abstinence versus very brief cessation advice, with biochemical verification in a subset.

EX Program is especially interesting if you need large-scale employer/health-plan deployment. It is developed with Mayo Clinic, has a substantial research portfolio, and is currently offered both free to consumers and commercially to organizations.

One important distinction: “clinically validated” does not necessarily mean FDA-cleared. Smoking-cessation digital therapeutics are generally supported by clinical-trial evidence rather than being FDA-authorized prescription digital therapeutics. If you're looking specifically for FDA-cleared/authorized DTx, the list is considerably narrower.

If you tell me whether you're looking for (1) an employer/health-plan benefit, (2) a product physicians can prescribe, or (3) a consumer app, I can narrow this to the best 3–5 options and compare RCT evidence, quit rates, FDA status, NRT integration, pricing, and payer/employer availability.

Several companies and research-backed platforms offer digital therapeutics (DTx) or clinically validated digital interventions for smoking and nicotine cessation . Unlike casual wellness or habit-tracking apps, these programs utilize evidence-based frameworks—such as Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT)—and have undergone clinical trials or randomized controlled trials (RCTs).

Prominent Providers and Platforms

• Click Therapeutics (Clickotine) : Clickotine is a comprehensive, evidence-based digital therapeutic platform designed for smoking cessation. It incorporates behavior modification techniques, mindfulness, peer support, and tracking tools. Click Therapeutics has evaluated Clickotine in multiple clinical trials and partnered with major health organizations and payers (like Magellan Health) to deliver integrated cessation programs.
• iCanQuit (developed via academic research/McClure et al.) : Evaluated extensively in large-scale randomized controlled trials funded by the National Institutes of Health (NIH), iCanQuit is a smartphone-delivered digital intervention based on Acceptance and Commitment Therapy (ACT). Clinical trials published in major addiction journals demonstrated that iCanQuit achieved significantly higher 12-month abstinence rates compared to standard non-customized apps.
• DynamiCare Health : DynamiCare offers a clinically validated digital therapeutic platform that utilizes contingency management (motivational incentives) coupled with app-based accountability, breath carbon monoxide tracking, and saliva/cotinine testing. They have received FDA Breakthrough Device Designation for addressing substance use and smoking cessation during pregnancy.
• Pivot (Carrot Inc.) : Pivot is an evidence-based digital smoking cessation program that pairs a mobile app with an FDA-cleared, at-home carbon monoxide breath sensor. The system is backed by clinical studies showing measurable engagement and quit outcomes, and it is widely distributed through employers and health plans.
• Alex Therapeutics & Pfizer : Alex Therapeutics developed a CBT-backed digital nicotine cessation program (marketed under names like Eila ). Partnering with major pharmaceutical companies like Pfizer, these platforms undergo dedicated clinical validation processes to commercialize regulated digital therapies internationally.

Would you like information on whether these digital programs are covered by major insurance or employer plans , or are you looking for options tailored to a specific patient demographic (such as pregnant individuals or those with comorbid conditions)?

Several companies and organizations offer clinically validated or evidence-based digital tools and therapeutics designed to aid in smoking cessation and nicotine dependence.

• Click Therapeutics (Clickotine) : Clickotine is a comprehensive, smartphone-based digital therapeutic designed for smoking cessation. It delivers cognitive and behavioral modification interventions, personalized coaching, and tracking tools, and it has been evaluated in multiple clinical studies and real-world learning trials demonstrating its impact on quit rates. It is frequently distributed via enterprise and health plan partnerships.
• CureApp (SC Nicotine Addiction Treatment App) : Developed in Japan, CureApp offers a clinically validated digital therapeutic for nicotine addiction that integrates a mobile app for cognitive behavioral therapy with a portable carbon monoxide (CO) checker. Clinical trials published for the system have shown statistically significant improvements in sustained smoking cessation rates.
• BrainsWay (Deep TMS) : While not a software app, BrainsWay offers an FDA-cleared non-invasive medical device platform utilizing Deep Transcranial Magnetic Stimulation (Deep TMS) specifically authorized as a short-term aid for smoking cessation in adults, backed by large randomized clinical trials [1.22].
• National Cancer Institute (Smokefree.gov / QuitGuide) : Though positioned as public health digital tools rather than commercial prescription digital therapeutics, the NCI provides evidence-based mobile apps (like QuitGuide) and structured text-messaging programs built directly around U.S. clinical practice guidelines for tobacco cessation.

If you are looking for a solution covered by insurance or an employer plan , or if you prefer a prescription app versus an over-the-counter tool , let me know so I can point you in the right direction.

Yes. If by “clinically validated” you mean a digital therapeutic with published randomized clinical evidence—not merely a wellness app—the field is fairly small.

The strongest current examples

An important regulatory distinction

There is currently a big difference between “clinically validated” and “FDA-cleared.” The FDA's current smoking-cessation information lists approved/cleared drugs and certain devices, but does not list a prescription digital therapeutic specifically cleared for smoking cessation.

There was an FDA-cleared digital therapeutic from Pear Therapeutics, but reSET-O was for opioid use disorder, not smoking cessation. FDA records classify it as a computerized behavioral-therapy device for substance-use disorders.

So if you're doing competitive/market research, I'd classify the landscape roughly as:

Tier 1 — strongest smoking-cessation clinical evidence

• 2Morrow / SmartQuit
• Quit Genius

Tier 2 — clinically studied comprehensive digital programs

• Pivot
• Smoke Free

Not equivalent: generic cessation apps, text-message programs, or AI quit coaches that have not demonstrated efficacy in a randomized controlled trial.

The WHO currently supports digital tobacco-cessation interventions as an adjunct or self-management tool, but notes that evidence certainty varies considerably by modality—moderate for text messaging, low for smartphone/AI interventions, and very low for internet-based interventions.

If you're evaluating this from a healthcare/market-access perspective, I can also give you a more rigorous landscape of every U.S. smoking-cessation DTx/company, clinical-trial size and endpoint, FDA status, payer/employer distribution, and whether it's available to consumers in 2026.